{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:46Z","timestamp":1793608186715,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.berh.2026.102132","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:29:21Z","timestamp":1774427361000},"page":"102132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex-related differences in psoriatic arthritis (PsA) treatment outcomes"],"prefix":"10.1016","volume":"40","author":[{"given":"Alicia","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1715","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 10","key":"10.1016\/j.berh.2026.102132_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.24242","article-title":"Measuring outcomes in psoriatic arthritis","volume":"72","author":"Ogdie","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.berh.2026.102132_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex- and gender-related differences in psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-9276-8-14","article-title":"Better science with sex and gender: facilitating the use of a sex and gender-based analysis in health research","volume":"8","author":"Johnson","year":"2009","journal-title":"Int J Equity Health"},{"issue":"2","key":"10.1016\/j.berh.2026.102132_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/biomedicines12020265","article-title":"Gender medicine and pharmacology","volume":"12","author":"Allegra","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41467-023-35808-6","article-title":"Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes","volume":"14","author":"Huang","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.berh.2026.102132_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.berh.2026.102132_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40618-023-02196-z","article-title":"Obesity: a gender-view","volume":"47","author":"Muscogiuri","year":"2023","journal-title":"J Endocrinol Investig"},{"issue":"10","key":"10.1016\/j.berh.2026.102132_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2471\/BLT.22.289310","article-title":"Differentiating sex and gender in health research to achieve gender equity","volume":"101","author":"Kaufman","year":"2023","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1186\/s12913-025-13020-0","article-title":"Gender differences in health-seeking behaviour: insights from the national health and morbidity survey 2019","volume":"25","author":"Rata Mohan","year":"2025","journal-title":"BMC Health Serv Res"},{"issue":"10250","key":"10.1016\/j.berh.2026.102132_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)31561-0","article-title":"Sex and gender: modifiers of health, disease, and medicine","volume":"396","author":"Mauvais-Jarvis","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.berh.2026.102132_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.220386","article-title":"Sex-specific differences in patients with psoriatic arthritis: a systematic review","volume":"50","author":"Coates","year":"2023","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2026.102132_bib12","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","article-title":"Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis","volume":"5","author":"Eder","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2026.102132_bib13","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/acr.24090","article-title":"Determinants of patient\u2010reported psoriatic arthritis impact of disease: an analysis of the association WithSex in 458 patients from fourteen countries","volume":"72","author":"Orbai","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.berh.2026.102132_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/annrheumdis-2012-201357","article-title":"Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis","volume":"72","author":"Eder","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102132_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103394","article-title":"Sex differences in biomarkers and biologic mechanisms in psoriatic diseases and spondyloarthritis","volume":"152","author":"Dang","year":"2025","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.berh.2026.102132_bib16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102132_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","article-title":"Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish early psoriatic arthritis register (SwePsA)","volume":"73","author":"Theander","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13075-025-03650-4","article-title":"Real-world sex differences in treatment persistence and reasons for discontinuation in psoriatic arthritis patients: results from the German RABBIT-SpA register","volume":"27","author":"Lindner","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.berh.2026.102132_bib19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","article-title":"Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British association of dermatologists biologic interventions register (BADBIR)","volume":"138","author":"Iskandar","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102132_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003570","article-title":"Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS)","volume":"9","author":"Pina Vegas","year":"2023","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.berh.2026.102132_bib21","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/rheumatology\/key140","article-title":"Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish health care Registers","volume":"57","author":"H\u00f8jgaard","year":"2018","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.berh.2026.102132_bib22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","article-title":"Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions","volume":"69","author":"Van Den Bosch","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2026.102132_bib23","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s10067-017-3769-4","article-title":"A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors","volume":"36","author":"Chimenti","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2026.102132_bib24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acr.22529","article-title":"Minimal disease activity and anti\u2013tumor necrosis factor therapy in psoriatic arthritis","volume":"67","author":"Haddad","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.berh.2026.102132_bib25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3899\/jrheum.211037","article-title":"Potential impact of sex and BMI on response to therapy in psoriatic arthritis: post hoc analysis of results from the SEAM-PsA trial","volume":"49","author":"Mease","year":"2022","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102132_bib26","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3899\/jrheum.181272","article-title":"Real-world longterm effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the rheumatic diseases Portuguese register","volume":"47","author":"Vieira-Sousa","year":"2020","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2026.102132_bib28","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","article-title":"Responses to Ixekizumab in Male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials","volume":"9","author":"Eder","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"suppl 10","key":"10.1016\/j.berh.2026.102132_bib29","article-title":"Comparison of secukinumab versus adalimumab efficacy by sex in psoriatic arthritis from a phase 3b, double-blinded, randomized, active-controlled study","volume":"72","author":"Wright","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001519","article-title":"Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study","volume":"7","author":"Ramonda","year":"2021","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.berh.2026.102132_bib31","article-title":"One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: real-world data from the BIOBADASER registry","volume":"21","author":"L\u00f3pez-Medina","year":"2025","journal-title":"Reumatol Cl\u00ednica Engl Ed"},{"issue":"4","key":"10.1016\/j.berh.2026.102132_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003538","article-title":"Differences in treatment response between female and male psoriatic arthritis patients during IL-12\/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial","volume":"9","author":"Koehm","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2026.102132_bib33","article-title":"Influence of biological sex on participant characteristics, Guselkumab efficacy and radiographic progression in active psoriatic arthritis: post hoc analysis of three randomized trials","author":"Gladman","year":"2025","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2342383","article-title":"Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials","volume":"35","author":"Merola","year":"2024","journal-title":"J Dermatol Treat"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002718","article-title":"Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension","volume":"9","author":"Eder","year":"2023","journal-title":"RMD Open"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102132_bib36","article-title":"Efficacy of Upadacitinib in Male and female patients with PsA: results from the SELECT-PsA 1 and 2 trials [abstract]","volume":"77","author":"Eder","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102132_bib37","article-title":"Sex and treatment-associated outcomes in patients with active psoriatic arthritis treated with deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial [abstract]","volume":"75","author":"Eder","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102132_bib38","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2665-9913(22)00008-X","article-title":"Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study","volume":"4","author":"Coates","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000638","article-title":"Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona psoriatic arthritis\/spondyloarthritis registry","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.berh.2026.102132_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.105116","article-title":"Structural damage is not a major driver of disease impact in patients with long-standing psoriatic arthritis undergoing systemic therapy","volume":"88","author":"Queiro","year":"2021","journal-title":"Jt Bone Spine"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13075-025-03518-7","article-title":"Burden and determinants of multi-b\/tsDMARD failure in psoriatic arthritis","volume":"27","author":"Haberman","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2026.102132_bib42","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/rheumatology\/kez505","article-title":"Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis","volume":"59","author":"Iannone","year":"2020","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2026.102132_bib43","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/acr.24593","article-title":"Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis","volume":"74","author":"Wong","year":"2022","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/bmb\/lds038","article-title":"Epidemiology and burden of osteoarthritis","volume":"105","author":"Litwic","year":"2013","journal-title":"Br Med Bull"},{"issue":"12","key":"10.1016\/j.berh.2026.102132_bib45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nrn3360","article-title":"Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon","volume":"13","author":"Mogil","year":"2012","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"10.1016\/j.berh.2026.102132_bib46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jpain.2008.12.001","article-title":"Sex, gender, and pain: a review of recent clinical and experimental findings","volume":"10","author":"Fillingim","year":"2009","journal-title":"J Pain"},{"issue":"9","key":"10.1016\/j.berh.2026.102132_bib47","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.joca.2024.04.002","article-title":"Sex differences in osteoarthritis prevalence, pain perception, physical function and therapeutics","volume":"32","author":"Segal","year":"2024","journal-title":"Osteoarthr Cartil"},{"issue":"6","key":"10.1016\/j.berh.2026.102132_bib48","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/jnr.23841","article-title":"Sex differences in pain","volume":"95","author":"Sorge","year":"2017","journal-title":"J Neurosci Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aet127","article-title":"Sex differences in pain: a brief review of clinical and experimental findings","volume":"111","author":"Bartley","year":"2013","journal-title":"Br J Anaesth"},{"issue":"5","key":"10.1016\/j.berh.2026.102132_bib50","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ejpain.2004.01.003","article-title":"Sex differences in pain and analgesia: the role of gonadal hormones","volume":"8","author":"Craft","year":"2004","journal-title":"Eur J Pain"},{"issue":"Supplement 1","key":"10.1016\/j.berh.2026.102132_bib51","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.pain.2007.09.028","article-title":"Modulation of pain by estrogens","volume":"132","author":"Craft","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.berh.2026.102132_bib52","article-title":"The obesity\u2013inflammation axis in psoriatic disease: mechanisms and therapeutic strategies","author":"Haberman","year":"2025","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102132_bib53","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2026.102132_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2025.105904","article-title":"Weighing in on obesity and psoriatic arthritis \u2013 time to move beyond association to robust randomised trials","volume":"92","author":"Siebert","year":"2025","journal-title":"Jt Bone Spine"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-017-0155-5","article-title":"Sex differences in drugs: the development of a comprehensive knowledge base to improve gender awareness prescribing","volume":"8","author":"Karlsson","year":"2017","journal-title":"Biol Sex Differ"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"10","key":"10.1016\/j.berh.2026.102132_bib57","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.berh.2026.102132_bib58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2026.102132_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60363-4","article-title":"Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis","volume":"385","author":"Jani","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.berh.2026.102132_bib60","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/03009742.2019.1602670","article-title":"Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population","volume":"48","author":"Hambardzumyan","year":"2019","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2026.102132_bib61","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1093\/rheumatology\/keaf311","article-title":"Sex differences in serum proteomic profiles in psoriatic arthritis","volume":"64","author":"Dang","year":"2025","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12875-016-0440-0","article-title":"The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study","volume":"17","author":"Thompson","year":"2016","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.berh.2026.102132_bib63","first-page":"1346","article-title":"Sex differences in response and persistence to biologic therapy in psoriatic arthritis: a 52\u2010Week analysis with extended long\u2010term outcomes","volume":"8","author":"Ohyachi","year":"2025","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102132_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13293-021-00366-3","article-title":"Gender-related variables for health research","volume":"12","author":"Nielsen","year":"2021","journal-title":"Biol Sex Differ"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:12:16Z","timestamp":1793607136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1521694226000173"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102132","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-related differences in psoriatic arthritis (PsA) treatment outcomes","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102132"}}